Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of atezolizumab + tiragolumab versus durvalumab after chemoradiotherapy in unresectable stage III non-small cell lung cancer
CTR20210309Phase 3Terminated
- Sponsor
- Roche
- Start
- Jul 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab, tiragolumab, durvalumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Jul 2021; status: terminated.
02
Drugs
atezolizumabtiragolumabdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20210309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210309.